ValuEngine upgraded shares of Alder BioPharmaceuticals (NASDAQ:ALDR) from a strong sell rating to a sell rating in a report published on Thursday, January 4th.

Several other research firms also recently commented on ALDR. Mizuho restated a buy rating and issued a $32.00 price target on shares of Alder BioPharmaceuticals in a research note on Wednesday, November 8th. BidaskClub upgraded shares of Alder BioPharmaceuticals from a strong sell rating to a sell rating in a research note on Friday, December 29th. Cowen began coverage on shares of Alder BioPharmaceuticals in a research note on Tuesday, September 26th. They issued an outperform rating and a $20.00 price target on the stock. BMO Capital Markets reiterated a buy rating and set a $22.00 price objective on shares of Alder BioPharmaceuticals in a research note on Wednesday, January 3rd. Finally, Royal Bank of Canada began coverage on shares of Alder BioPharmaceuticals in a research note on Thursday, September 14th. They set an outperform rating and a $17.00 price objective on the stock. Three research analysts have rated the stock with a sell rating, two have assigned a hold rating and eleven have given a buy rating to the company. The company currently has a consensus rating of Buy and a consensus target price of $27.93.

How to Become a New Pot Stock Millionaire

Alder BioPharmaceuticals (NASDAQ:ALDR) opened at $15.00 on Thursday. Alder BioPharmaceuticals has a one year low of $8.60 and a one year high of $25.45. The company has a market cap of $1,020.00, a PE ratio of -2.79 and a beta of 2.48.

Alder BioPharmaceuticals (NASDAQ:ALDR) last released its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.92) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.21) by $0.29. During the same quarter last year, the company earned ($0.70) earnings per share. equities research analysts forecast that Alder BioPharmaceuticals will post -5.14 EPS for the current fiscal year.

In other news, insider Mark James Litton sold 16,519 shares of the stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $10.80, for a total value of $178,405.20. Following the completion of the transaction, the insider now owns 116,451 shares of the company’s stock, valued at $1,257,670.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 10.60% of the stock is currently owned by corporate insiders.

Several hedge funds have recently bought and sold shares of the company. Legal & General Group Plc lifted its holdings in shares of Alder BioPharmaceuticals by 2.6% in the second quarter. Legal & General Group Plc now owns 15,496 shares of the biopharmaceutical company’s stock worth $177,000 after acquiring an additional 400 shares during the last quarter. The Manufacturers Life Insurance Company lifted its holdings in shares of Alder BioPharmaceuticals by 1.9% in the second quarter. The Manufacturers Life Insurance Company now owns 37,488 shares of the biopharmaceutical company’s stock worth $430,000 after acquiring an additional 698 shares during the last quarter. Voya Investment Management LLC lifted its holdings in shares of Alder BioPharmaceuticals by 8.4% in the second quarter. Voya Investment Management LLC now owns 22,304 shares of the biopharmaceutical company’s stock worth $255,000 after acquiring an additional 1,734 shares during the last quarter. Russell Investments Group Ltd. lifted its holdings in shares of Alder BioPharmaceuticals by 7.2% in the second quarter. Russell Investments Group Ltd. now owns 42,416 shares of the biopharmaceutical company’s stock worth $486,000 after acquiring an additional 2,837 shares during the last quarter. Finally, Teachers Advisors LLC lifted its holdings in shares of Alder BioPharmaceuticals by 3.8% in the second quarter. Teachers Advisors LLC now owns 84,705 shares of the biopharmaceutical company’s stock worth $970,000 after acquiring an additional 3,091 shares during the last quarter. 96.77% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “Alder BioPharmaceuticals (NASDAQ:ALDR) Upgraded to Sell at ValuEngine” was originally published by Marea Informative and is the property of of Marea Informative. If you are reading this news story on another publication, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be accessed at https://www.mareainformativa.com/2018/01/30/alder-biopharmaceuticals-aldr-lifted-to-sell-at-valuengine-updated-updated-updated.html.

About Alder BioPharmaceuticals

Alder BioPharmaceuticals, Inc, is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Alder BioPharmaceuticals (NASDAQ:ALDR)

Receive News & Ratings for Alder BioPharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder BioPharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.